Cangene
Cangene is a fully integrated biopharmaceutical company that develops and manufactures immune therapeutics and specialty biologics. Its products include WinRho® SDF and Accretropin, a growth hormone therapy for endocrine disorders, serving patients with immune and growth-related conditions.
- Company typePrivate
- Founded1984
- HeadquartersBaltimore, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Cangene does
Cangene is a fully integrated biopharmaceutical company founded in 1984, classified as a for-profit private entity with 1,001-5,000 employees. The company developed and manufactured immune therapeutics and specialty biologics, with WinRho® SDF established as its first commercial drug. Beyond immune therapeutics, Cangene expanded into the endocrine therapeutics market through the development and commercialization of Accretropin, a growth hormone product indicated for pediatric growth hormone deficiency, chronic kidney disease, and Turner syndrome.
Cangene's business model centered on developing, manufacturing, and commercializing specialty biologic drugs distributed to healthcare providers, hospitals, and patients with immune-related and endocrine disorders. The company's integrated operations spanned the full biologic product lifecycle from development through commercial manufacturing. In July 2009, Cangene pursued pipeline expansion via the acquisition of Twinstrand Therapeutics, though the financial terms of that transaction were undisclosed.
Based on the available source material, Cangene bioPharma appears to no longer operate as an independent standalone entity and is referenced primarily in historical and career contexts. The company's website is listed as cangene.com, and historical firmographic data places its operational base in Baltimore, United States. Specific revenue figures, current headcount trends, pricing models, and detailed customer segmentation are not available in the source data, limiting the granularity of any forward-looking assessment.
Cangene firmographics
Firmographics- Name
- Cangene
- Website
- https://cangene.com
- Company type
- Private
- Founded year
- 1984
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Cangene is a fully integrated biopharmaceutical company that develops and manufactures immune therapeutics and specialty biologics. Its products include WinRho® SDF and Accretropin, a growth hormone therapy for endocrine disorders, serving patients with immune and growth-related conditions.
- Ownership category
- akta.pro rank
Where Cangene is headquartered
LocationHeadquarters
- HQ city
- Baltimore
- HQ country
- United States
- HQ region
- North America
Markets served
Cangene business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Supply Chain
Cangene product offering
Product offeringCore offering
Cangene is a fully integrated developer and manufacturer of immune therapeutics. The company developed and commercialized products such as WinRho® SDF, an immune therapeutic, and Accretropin, a recombinant growth hormone therapy used for pediatric growth hormone deficiency, chronic kidney disease, and Turner syndrome. Operations span biologics development, manufacturing, and commercialization.
Product overview
Cangene is a biopharmaceutical company that produced Accretropin, a growth hormone therapy. The company operated in the biopharma sector, with its products addressing endocrine disorders including pediatric growth hormone deficiency, chronic kidney disease, and Turner syndrome. Based on the available source data, Cangene appears to have been acquired or merged, as the Accretropin brand is now referenced within market research as a Cangene product.
Differentiator
Problem solved
Functional benefit
Brands
- Accretropin: Growth hormone product for pediatric growth hormone deficiency, chronic kidney disease, and Turner syndrome
Products and services
- WinRho® SDF
- Accretropin
Companies that use Cangene
Customer profileIdeal customer profiles1 record
Cangene technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Cangene partnerships and signals
Strategic signalRecent moves4 records
Expansion highlights2 records
Cangene competitors and assessment
Company assessmentMarket position
Competitive moat3 records
Key highlights6 records
Customer concentration
Cangene social profiles
Digital presenceCangene financial estimates
Financial estimateRevenue estimate
Valuation estimate
Cangene leadership team
Management profileNumber of profiles
Cangene funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Cangene M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Cangene
What does Cangene do?
Cangene is a fully integrated developer and manufacturer of immune therapeutics. The company developed and commercialized products such as WinRho® SDF, an immune therapeutic, and Accretropin, a recombinant growth hormone therapy used for pediatric growth hormone deficiency, chronic kidney disease, and Turner syndrome. Operations span biologics development, manufacturing, and commercialization.
Is Cangene a public or private company?
Cangene is a private company. It is classified as unknown and is currently operating.
When was Cangene founded?
Cangene was founded in 1984. It employs 1,001 to 5,000 people.
Where is Cangene based?
Cangene is headquartered in Baltimore, United States, in the North America region.
Does Cangene have an API?
No public API is recorded for Cangene.